HNU-23 60K

VITAMIN D3 60000 IU 5 ml ORAL SOLUTION








VITAMIN D3 60000 IU 5 ml ORAL SOLUTION



BACKGROUND:

- ★ Vitamin D is a precursor of the active hormone 1,25(OH)2D (calcitriol).
- ★ Vitamin D plays a primary role in calcium, phosphorus, and bone metabolism.¹
- * Approximately 75% of orally administered vitamin D is absorbed in the jejunum and ileum.²
- * Daily doses of vitamin D3 between 1000 and 4000 IU/day are needed in order to achieve and maintain serum 25OHD concentrations of at least 30 ng/ml, starting from a point of vitamin D sufficiency in healthy adults.¹

ESTABLISHED AND POTENTIAL IMMUNE-MODULATING ROLE IN IBD2:



CLINICAL EVIDENCE³:

ORAL NANO VITAMIN D SUPPLEMENTATION REDUCES DISEASE ACTIVITY IN ULCERATIVE COLITIS A DOUBLE-BLIND RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED TRIAL

AIM:

To study the effect of oral Nano Vitamin D3 supplementation on disease activity in active UC (Ulcerative Colitis).


STUDY SETTING & STUDY DESIGN:

- The study was a single-center double-blind randomized parallel placebo-controlled trial.
- * Patients (n=60) with active UC and vitamin D <40 ng/mL were randomized to receive either oral Nano vitamin D (n=30) (60,000 IU/daily) or Placebo (n=30) for 8 days.
- * They were evaluated for disease activity (UCDAI scores, C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin) at baseline and reassessed at 4 weeks.

OUTCOMES:


AT BASELINE	BASELINE PARAMETERS
Vitamin D Group (N=30)	Increased from 15.4 (IQR, 13.38 ng/dL) to 40.83, (IQR, 32 ng/dL) (P <0.0001)
Placebo Group (N=30)	Increased marginally from median 13.45 (IQR, 17.34) to 18.85, (IQR, 21.46) (P =0.027)

REDUCTION IN UCDAI BY 3 POINTS



ulcerative colitis disease activity index.

IMPROVEMENT IN DISEASE SEVERITY



CONCLUSION:

Oral Nano vitamin D supplementation in active UC is associated with a reduction in disease activity and severity grade and is seen more often in those who achieved a target vitamin D level of 40 ng/mL



DESCRIPTION:

HNU-D3 Solution contains Cholecalciferol IP 60,000 IU (International units) in Nano droplet form. Cholecalciferol (Vitamin D3) is a fat soluble vitamin, that helps the body to absorb calcium and phosphorous found in food and supplements.

INDICATION:

For treatment and prevention of vitamin D deficiency states like in,



KEY FEATURES:

- Vitamin D insufficiency is present in up to 96% of patients before liver transplantation.
- Active vitamin D hormone exerts physiological and pharmacological effects by binding to the VDR and then sustains a conformational change.
- HNU-D3 Oral solution helps in boosting immunity and increasing resistance against infection.
- It regulates inflammation and immunity in association with reducing the disease symptoms of several gastrointestinal diseases.
- It may contribute to detoxification of toxic and chemical compounds, maintaining gut homeostasis.
- Vitamin D, 1,25(OH))2D3 stimulates intestinal absorption of orally ingested calcium and phosphate, tubular reabsorption of calcium filtered in the kidney, and mobilization of calcium and phosphate stores from the skeleton by stimulating maturation of osteoclasts.

DOSAGE:

Vitamin D3 60000 IU to be given once a week for a period of 8 weeks, followed by maintenance daily dose as directed by the physician.

PRESENTATION:

Vitamin D3 60000 IU /5 ml in a 5 ml bottle.

Reference:

- 1. Vitamin D status Pappa et al.
- 2. Current Drug Metabolism, 2012, 13.
- 3. J Clin Gastroenterol _ Volume 53, Number 10, November/December 2019.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

